,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-02-14 23:50:00,"On Feb 13, we retained St. Jude Medical Inc. ( STJ ) at Neutral, following its fourth-quarter results.",0.029024070128798485,0.019218809902668,0.9517570734024048,neutral,0.009805260226130486
1,2013-02-14 23:50:00,"In spite of the upbeat results, the medical devices giant provided a conservative 2013 guidance.",0.21123941242694855,0.5988585352897644,0.18990206718444824,negative,-0.38761913776397705
2,2013-02-14 23:50:00,"On Jan 23, St. Jude posted fourth-quarter 2013 adjusted earnings per share of 92 cents, which topped the Zacks Consensus Estimate by 2 cents and transcended the year-ago earnings of 86 cents.",0.941372275352478,0.02792050689458847,0.0307072214782238,positive,0.9134517908096313
3,2013-02-14 23:50:00,"Revenues dropped 2% (down 1% in constant currency) year over year to $1,372 million, just ahead of the Zacks Consensus Estimate of $1,370 million.",0.01669231243431568,0.9738448262214661,0.009462838061153889,negative,-0.9571524858474731
4,2013-02-14 23:50:00,The company's earnings have also managed to beat the Zacks Consensus Estimates in the last four quarters with an average surprise of 2.36%.,0.9558330774307251,0.02553310990333557,0.018633875995874405,positive,0.9302999973297119
5,2013-02-14 23:50:00,"Over the past 30 days, the Zacks Consensus Estimates for 2013 and 2014 has moved up by 4 cents and 3 cents to $3.70 and $3.97, respectively.",0.9388678669929504,0.02577522210776806,0.03535686433315277,positive,0.9130926728248596
6,2013-02-14 23:50:00,"However, St. Jude's revenue guidance for 2013 looks dismal due to an extremely challenging healthcare environment.",0.020007852464914322,0.9595274329185486,0.020464729517698288,negative,-0.9395195841789246
7,2013-02-14 23:50:00,"Meanwhile, we are impressed by the company's focus on cost savings, restructuring and share repurchase programs to boost its bottom line.",0.9386925101280212,0.014764494262635708,0.04654291644692421,positive,0.9239280223846436
8,2013-02-14 23:50:00,"Sales for 2013 are expected to be down 1%-2% year over year, while adjusted earnings for the year are forecast to be up 6%-7%.",0.016669848933815956,0.9707756042480469,0.012554607354104519,negative,-0.9541057348251343
9,2013-02-14 23:50:00,A still soft Cardiac Rhythm Management (CRM) market along with issues regarding the ICD leads has increased investor concerns.,0.18849298357963562,0.7427778840065002,0.06872919201850891,negative,-0.554284930229187
10,2013-02-14 23:50:00,"However, multiple growth drivers and an efficient management team should leverage long-term growth for the company.",0.9186296463012695,0.013586652465164661,0.06778370589017868,positive,0.9050430059432983
11,2013-02-14 23:50:00,"Other Stocks to Consider

St. Jude has a Zacks Rank #3 (Hold).",0.08474823832511902,0.07571461796760559,0.8395371437072754,neutral,0.009033620357513428
12,2013-02-14 23:50:00,"While we remain on the sidelines regarding St. Jude, other large-cap medical products companies worth a look are Medtronic, Inc. ( MDT ), Covidien plc ( COV ) and Edwards Lifesciences Corp. ( EW ).",0.05573836714029312,0.008711479604244232,0.9355502128601074,neutral,0.04702688753604889
13,2013-02-14 23:50:00,All three are Zacks Rank #2 (Buy) stocks.,0.3123508393764496,0.03187227621674538,0.655776858329773,neutral,0.2804785668849945
14,2013-02-14 23:50:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
15,2013-02-14 23:50:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
